Strategic Shift at Sutro Biopharma: Insider Option Grants Signal Confidence in Oncology Milestones
Explore how Sutro Biopharma’s zero‑price insider option grants signal confidence and modest dilution ahead of key oncology milestones, and what this means for investors.
3 minutes to read